Anavex Life Sciences Corp. (AVXL)
NASDAQ: AVXL · IEX Real-Time Price · USD
5.09
+0.03 (0.59%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Anavex Life Sciences Cash Flow Statement

Millions USD. Fiscal year is Oct - Sep.
Year 2023202220212020201920182017201620152014 2013 - 2005
Net Income
-47.51-47.98-37.91-26.28-26.29-17.25-13.46-14.74-12.11-9.97
Upgrade
Depreciation & Amortization
0000000000
Upgrade
Share-Based Compensation
16.3718.388.234.886.435.524.145.061.630.64
Upgrade
Other Operating Activities
3.355.36-0.710.121.34-0.850.310.446.256.67
Upgrade
Operating Cash Flow
-27.79-24.24-30.38-21.29-18.53-12.58-9.02-9.24-4.23-2.66
Upgrade
Capital Expenditures
000000000-0
Upgrade
Investing Cash Flow
000000000-0
Upgrade
Share Issuance / Repurchase
29.6522158.7928.7517.838.1727.273.1712.340.37
Upgrade
Debt Issued / Paid
0000000-0.03-0.0910
Upgrade
Other Financing Activities
--0.71-5.55-0.4-0.05-0.1----0.79
Upgrade
Financing Cash Flow
29.6521.29153.2428.3517.788.0727.273.1312.269.58
Upgrade
Net Cash Flow
1.87-2.95122.867.06-0.75-4.5118.25-6.18.036.92
Upgrade
Free Cash Flow
-27.79-24.24-30.38-21.29-18.53-12.58-9.02-9.24-4.23-2.66
Upgrade
Free Cash Flow Per Share
-0.35-0.32-0.43-0.37-0.38-0.28-0.22-0.26-0.23-0.27
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).